Pfizer’s PFE stock hit a new 52-week low of $20.92 on Wednesday but recovered thereafter and closed at $22.49 Though the ...

Five years ago, volunteers rolled up their sleeves in the first clinical trial of a vaccine against COVID-19, as the new pandemic surged around them. By a year later, 66 million American adults had ...

Vaccination campaigns have nearly eradicated some of the most deadly and transmissible diseases. In a rising tide of vaccine ...

A passion for learning took her from apartheid South Africa to a beer brewery to becoming a healthcare consultant, all before ...

These five well-known dividend stocks were beaten down in the recent selling but will remain attractive long after the tariff ...

Concern is growing among public health experts that anti-vaccine sentiments within federal and state governments may derail ...

Pfizer’s blockbuster COVID era has officially left the chat, but the pharmaceutical giant is scripting a bold new chapter.

Officials say the Army has reenlisted more than 23 soldiers who were discharged for refusing the COVID-19 vaccine.

Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.

From stock decline to Hold rating, explore their growth strategy, client focus, and potential gains. Click for my MRVI update ...

As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...